Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
BlackBerry’s QNX software has secured new deployments in industrial automation, robotics, and medical AI.
The QNX platform is being adopted in a new AI powered heart pump developed by Johnson & Johnson.
These wins extend QNX beyond its traditional automotive base into additional embedded and safety critical use cases.
For investors watching TSX:BB, this QNX expansion comes with the stock at CA$12.86 and strong recent momentum. The share price is up 51.3% over the past 30 days, 146.4% year to date, and 131.3% over the past year, while the 5 year return is down 19.2%. That mix of longer term weakness and recent strength shapes how many investors may look at the new QNX use cases.
These developments introduce new context for how QNX might fit into industrial, robotics, and medical equipment spending. Investors may want to watch how BlackBerry discloses traction in these areas over time, including any updates on deployments like the Johnson & Johnson AI heart pump and other non automotive contracts.
Stay updated on the most important news stories for BlackBerry by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on BlackBerry.
TSX:BB Earnings & Revenue Growth as at Jun 2026
2 things going right for BlackBerry that this headline doesn’t cover.
Quick Assessment
❌ Price vs Analyst Target: At CA$12.86, the stock trades about 123% above the CA$5.77 analyst price target.
❌ Simply Wall St Valuation: Shares are trading 94.4% above the estimated fair value, indicating an overvalued status.
✅ Recent Momentum: The stock is up 51.3% over the past 30 days, reflecting very strong short term momentum.
There’s only one way to know the right time to buy, sell or hold BlackBerry. Head to Simply Wall St’s company report for the latest analysis of BlackBerry’s Fair Value.
Key Considerations
📊 QNX wins in industrial automation, robotics, and medical AI, including the Johnson & Johnson heart pump, broaden BlackBerry’s addressable embedded and safety critical market.
📊 Watch for segment disclosures on QNX revenue mix, new non automotive design wins, and any commentary on pricing or contract duration tied to these deployments.
⚠️ With the share price far above both analyst targets and estimated fair value, valuation risk may be high if expectations for QNX growth or margins do not align with future results.
Dig Deeper
For the full picture including more risks and rewards, check out the complete BlackBerry analysis. Alternatively, you can check out the community page for BlackBerry to see how other investors believe this latest news will impact the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BB.TO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com